In the United States, more than 70,000 people are diagnosed with non-Hodgkin’s lymphoma each year, which is caused by excessive proliferation of immune cells in the body’s lymph nodes. The most common is diffuse large B-cell lymphoma (DLBCL), which accounts for about 1/3 of lymphomas, and about half of these tumors are resistant to chemotherapy and immunotherapy. Olim lymphoma sit a TEXTUS ad lymphatica attinet, est causa, quare altiore structuram cell a TEXTUS ad necdum plane inimicus, et conformant cellulae, quae patere mechanica viribus fluidorum sicut fluxus.
Hae copiae fluidi sunt, ut explorarentur quod inquisitores ad tumore resistentibus est developed "lymphoma microreactor", quae vitam machinam humanae fluxus, rhoncus eu lorem lymphoma, similes dispositiones in series vasa lymphatica attinet et nodorum lymphaticorum.
Bigas scriptor cell ad latus-culturae includit fluxus microreactor ad aethereum thalamum quae media cultus (liquor) in sinu per angustus Resistentes Superavit channel, quam ut scopus lentus humor fluxus simulare, vasorum et nodorum lymphaticorum nodi partes. Dum tentat de diversis subpopulations DLCBL lymphoma, et inventus est investigatio quadrigis enim secundum certa cuique genere mutationes in B cellula in cellulam receptor moleculis inventus superficiem respondit aliter viribus, rhoncus eu lorem. Fluidum autem expressio inveniri bigas potentiae regulat gradus Integrin adhesin et B-cell receptoribus. Non est crucem inter suas inquietari implicat, atque integrin B receptor annuit cellulam, quae auxiliatus explicare possunt resistentiam aliquam similitudinem anorum.
What is remarkable is that the same tumor subtype responds differently to mechanical forces. If we can understand the role of biophysical stimulation, we can know why some lymphomas are sensitive to treatment, while others are refractory, then we will be able to treat more patients. It is important to understand the factors that regulate B-cell receptor signaling because this pathway is a key target for new therapeutic drugs, and several of them are in clinical trials. Quia magis details, placere vocatio CancerFax.
